Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nelfinavir · 5 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Ritonavir | DRUG | - |
| Nelfinavir mesylate | DRUG | - |
| Saquinavir | DRUG | - |
| Delavirdine mesylate | DRUG | - |
| Stavudine | DRUG | - |
| Lamivudine | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Patients must have: * HIV RNA \>= 5000 copies/ml by Amplicor assay. * Signed, informed consent from parent or legal guardian for patients less than 18 years old. Previous treatment with antiretrovirals.
Top 20 of 28 competitors
Nelfinavir is an investigational small molecule being developed for the treatment of HIV Infections. It is currently in Phase 3 clinical development, though all five recorded trials have been completed. The drug is being studied in combination with other antiretroviral therapies in HIV-1 infected patients.
Nelfinavir is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials for this small molecule drug candidate in the infectious disease therapeutic area, specifically targeting HIV Infections.
Nelfinavir is in Phase 3 clinical development. However, all five clinical trials associated with the drug have been completed, with no active trials currently ongoing. The completed trials enrolled a total of 1,372 participants across various studies.
Nelfinavir has been studied in five completed clinical trials, including NCT00002178, NCT00002374, NCT00002378, and NCT00002380. These trials evaluated the drug in combination with other antiretrovirals in HIV-1 infected patients, including a pediatric study. The trials were conducted primarily in the United States and other countries.
Nelfinavir is an investigational drug and is not FDA approved. It is currently in Phase 3 clinical development, but all recorded trials have been completed. The drug has not received approval for the treatment of HIV Infections and remains under investigation.